UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 1.160

Sortiert nach

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Journal of clinical oncology, 2007-08, Vol.25 (22), p.3230-3237

2007

Volltextzugriff (PDF)

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Journal of clinical oncology, 2006-10, Vol.24 (30), p.4914-4921

2006

Volltextzugriff (PDF)

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Clinical cancer research, 2008-12, Vol.14 (23), p.7884-7895

2008

Volltextzugriff (PDF)

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

Clinical cancer research, 2010-11, Vol.16 (22), p.5591-5602

2010

Volltextzugriff (PDF)

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2015-12, Vol.107 (12), p.djv258-djv258

2015

Volltextzugriff (PDF)

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer

Journal of clinical oncology, 2016-10, Vol.34 (30), p.3638-3647

2016

Volltextzugriff (PDF)

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

Oncology, 2007-01, Vol.72 (3-4), p.152-159

2007

Volltextzugriff (PDF)

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

Breast cancer research and treatment, 2017-10, Vol.165 (3), p.601-609

2017

Volltextzugriff (PDF)

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice

Cancer research (Chicago, Ill.), 2009-07, Vol.69 (14), p.5643-5647

2009

Volltextzugriff (PDF)

Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery

ClinicoEconomics and outcomes research, 2012-01, Vol.4 (default), p.169-176

2012

Volltextzugriff (PDF)

Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e21507-e21507

2018

Volltextzugriff (PDF)

Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal

Journal of clinical oncology, 2016-02, Vol.34 (4_suppl), p.TPS786-TPS786

2016

Volltextzugriff (PDF)

Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.TPS3096-TPS3096

2015

Volltextzugriff (PDF)

Minor response rate to predict patient survival

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.3635-3635

2013

Volltextzugriff (PDF)

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

JNCI : Journal of the National Cancer Institute, 2015-12, Vol.107 (12), p.1

2015

Volltextzugriff (PDF)

Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer

Cancer research (Chicago, Ill.), 2015-05, Vol.75 (9_Supplement), p.PD5-1-PD5-1

2015

Volltextzugriff (PDF)

BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.8042-8042

2014

Volltextzugriff (PDF)

Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.4054-4054

2012

Volltextzugriff (PDF)

BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2013-05, Vol.31 (15_suppl), p.TPS8118-TPS8118

2013

Volltextzugriff (PDF)

Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3587-3587

2012

Volltextzugriff (PDF)

Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC)

Journal of clinical oncology, 2012-05, Vol.30 (15_suppl), p.3531-3531

2012

Volltextzugriff (PDF)

A Human Nuclear Uracil DNA Glycosylase is the 37-kDa Subunit of Glyceraldehyde-3-Phosphate Dehydrogenase

Proceedings of the National Academy of Sciences - PNAS, 1991-10, Vol.88 (19), p.8460-8464

1991

Volltextzugriff (PDF)

In Reply

Journal of clinical oncology, 2008-05, Vol.26 (13), p.2230-2231

2008

Volltextzugriff (PDF)

Tumor Necrosis Factor-α and lnterieukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

Cancer research (Chicago, Ill.), 2009, Vol.69 (14), p.5643-5647

2009

Volltextzugriff (PDF)

Predictive markers of cetuximab efficacy in metastatic colorectal cancer

Current colorectal cancer reports, 2008-10, Vol.4 (4), p.184-192

2008

Volltextzugriff (PDF)

1 – 25 von 1.160

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.073)
Mit Volltextzugriff
(1.060)

Publikationsform

4 weitere anzeigen...

Weniger anzeigen...

Sprache

5 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(2)
... seit 90 Tagen
(12)

Menü

Weitere Dienste

Einstellungen

Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab

Multicenter Phase II and Translational Study of Cetuximab in Metastatic Colorectal Carcinoma Refractory to Irinotecan, Oxaliplatin, and Fluoropyrimidines

Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab

Germline Polymorphisms in Genes Involved in the IGF1 Pathway Predict Efficacy of Cetuximab in Wild-type KRAS mCRC Patients

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

The BATTLE-2 Study: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer

Impact and Management of Skin Toxicity Associated with Anti-Epidermal Growth Factor Receptor Therapy: Survey Results

A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer

Tumor necrosis factor-alpha and interleukin-1 antagonists alleviate inflammatory skin changes associated with epidermal growth factor receptor antibody therapy in mice

Retrospective US database analysis of drug utilization patterns, health care resource use, and costs associated with adjuvant interferon alfa-2b therapy for treatment of malignant melanoma following surgery

Relationship between pre-treatment organ-specific tumor burden (TB) and response to immunotherapy in advanced melanoma (MEL)

Phase II study of ADXS11-001 in patients with persistent/recurrent, locoregional or metastatic squamous cell carcinoma of the anorectal canal

Phase I study evaluating high dose ADXS11-001 treatment in women with carcinoma of the cervix

Minor response rate to predict patient survival

A Randomized Phase II/III Study of Dalotuzumab in Combination With Cetuximab and Irinotecan in Chemorefractory, KRAS Wild-Type, Metastatic Colorectal Cancer

Abstract PD5-1: Results from the phase 2 trial of ridaforolimus, dalotuzumab, and exemestane compared to ridaforolimus and exemestane in advanced breast cancer

BATLLE-2: KRAS mutation and outcome in a biomarker-integrated study in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC)

Tumor IGF-1 expression as a predictive biomarker for IGF1R-directed therapy in advanced pancreatic cancer (APC)

BATTLE-2 program: A biomarker-integrated targeted therapy study in previously treated patients with advanced non-small cell lung cancer (NSCLC)

Activity of the anti-IGF-1R antibody dalotuzumab (MK-0646) in KRAS-mutant colorectal cancer: Preclinical and clinical data

Molecular analysis of the randomized phase II/III study of the anti-IGF-1R antibody dalotuzumab (MK-0646) in combination with cetuximab (Cx) and irinotecan (Ir) in the treatment of chemorefractory KRAS wild-type metastatic colorectal cancer (mCRC)

A Human Nuclear Uracil DNA Glycosylase is the 37-kDa Subunit of Glyceraldehyde-3-Phosphate Dehydrogenase

In Reply

Tumor Necrosis Factor-α and lnterieukin-1 Antagonists Alleviate Inflammatory Skin Changes Associated with Epidermal Growth Factor Receptor Antibody Therapy in Mice

Predictive markers of cetuximab efficacy in metastatic colorectal cancer

Suchergebnisse filtern